Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2898)	6/30/2010 12:43:10 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

DRRX is trying to reverse its latest 2 day slide.<g> The stock is up 7.49% on volume about half its ADV. bigcharts.marketwatch.com According to a note on Reuters, DEXX said last week that its experimental pain drug, Posidur, met one of the two main goals of a mid-stage trial in Europe. And as previously mentioned, earlier this month DRRX announced that it had entered into e license agreement with HSP to develop and market POSIDUR in the U.S. and Canada. Under terms of that agreement, HSP will make an upfront payment of $27.5M, with the potential for up to an additional $185M in performance milestone payments based on the successful development, approval and commercialization of POSIDUR in the U.S. and Canada. <g> The ACTAY is $4 DRRX has now resistance at the $3.50; $2.753 and the more important looking one at the $3 level.<g> bigcharts.marketwatch.com However, DRRX has NLTD, and with some good news, it could get to the $4 level.<g> bigcharts.marketwatch.com Bernard